View Author
patient response t-cell hepatitis therapy hepatitis c hcv-speci load decrease study assay virus treatment baseline ribavirin hcv mono-infected patients hepatitis c virus fi rst phase decrease hcv /hiv patients mono-infected slope pegifn -␣/ribavirin therapy hcv-speci fic t-cells interferon infection week 4 analysis outcome phase genotype ifn -␥ production expansion arend fi rst-phase cd 8+ t-cells virological response peptide hcv-rna group kinetic peginterferon hepatology rst-phase decline model pegifn t-cell responses liver pre-treatment proliferation responder netherland virological peginterferon -␣ hcv mono-infected press signi article zeuzem ifn -␥ difference 12- cd 4+ non-svr hepatitis c mono-infected combination production press j.e week 12 utrecht rvr patients ficiency manuscript expansion assay peginterferon-alfa barne plasma ficant -␣/ribavirin non-rvr
2 Most Recent Publications
|
T-cell responses at baseline and during therapy with peginterferon-α and ribavirin are not associated with outcome in chronic hepatitis C infected patients
(Article)
Arends, J.E. Claassen, M.A.A. Berg, C.H.S.B. van den Nanlohy, N.M. Erpecum, K.J. van Baak, B.C. Hoepelman, I.M. Boonstra, P.A. Baarle, D. van |
2010-09-01
|
|
Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCVHIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2aribavirin therapy
(Article)
Arends, J.E. Stuart, J.C. Baak, L.C. Ende, M.E. van der Erpecum, K.J. van Simons, C.P.M. Boland , G.J. Baarle, D. van Hoepelman, I.M. |
2009-12-01
|
